Sun Pharma reported 2.56% year-on-year (YoY) increase in its consolidated net profit at Rs 3,117.95 crore in Q2FY26 from Rs 3,040.16 crore in Q2FY25.

The pharmaceutical major reported revenue from operations at Rs 14,478.31 crore against Rs 13,291.39 crore in Q2FY25.

Key highlights from Sun Pharma Q2FY26

On sequential basis the company reported 36.83% jump in consolidated net profit and 4.53% surge in revenue.

EBITDA stood at Rs. 4,527.1 crore, up 14.9% and EBITDA margin recorded at 31.3%. The company noted that the R&D investment was Rs. 782.7 crore that is 5.4% of sales.

The Q2 release highlights that formulation sales in India were Rs. 4,734.8 crore, registering a growth of 11%. India Formulation sales accounted for 32.9% of total consolidated sales for the quarter.

Sun Pharma ha

See Full Page